Shares of Ligand Pharmaceuticals Inc (NASDAQ: LGND) have recently surpassed the average analyst 12-month target price of $144.75, trading at $146.32 per share. Analysts are now considering whether to downgrade their valuations or adjust their target prices in light of the stock’s performance.
Among eight analysts covering Ligand, the prices range from a low of $125.00 to a high of $162.00, with a standard deviation of $12.406. Currently, there are six strong buy ratings and one buy rating, resulting in an average rating of 1.14, where 1 is a strong buy.
